EFFECT OF FAVIPIRAVIR USE ON INR, PT, APTT TESTS OF COVID-19 PATIENTS
Mehmet Ali Gul, Nezahat Kurt, Mustafa Capraz, Alpaslan Ozturk
The 2019 coronavirus disease (COVID-19) has caused millions of cases worldwide. As the pandemic progresses, understanding the effects of this disease remains important. We aimed to examine the hematological effects of the disease. The research was carried out as a retrospective study, 50 patients using favipiravir and 50 patients not using favipiravir who had positive COVID-19 RT-PCR test in nasal and throat swabs were included in the study. INR, PTT, aPTT tests were evaluated on all patients. Results of patients using favipiravir; INR 1.3±0.2, PT(s) 16.4±3.4, aPTT(s) 40.7±10.1, while the results of patients who did not use favipiravir were INR 1,2±0.2, PT(s) 14.6±2.5, aPTT(s) was found 38.4±7.8. While PT and INR were found to significantly higher in patients using favipiravir (p<0.05), the elevation in aPTT values was not significant. As a consequence, it was obtained that favipiravir prolongs the clotting time. In the light of these results, it is recommended to consider this in anticoagulant therapy used for treatment.
Information This study was presented as an oral presentation at the VII. Turkey In Vitro Diagnostics (IVD) Symposium 2022. We would like to thank the staff and doctors of Sabuncuoğlu Şerefeddin Training and Research Hospital (especially laboratories and clinics related to COVID-19), who worked with great dedication.
Conflicts of interest The authors declare that there are no potential conflicts of interest relevant to this article. Gul M. A., Kurt N., Capraz M., Ozturk A. (2022) . Effect of Favipiravir Use on INR, PT, aPTT Tests of 4(3), [14] [15] [16] [17] [18] [19] [20]
References
Akbari, Tabrizi, Lankarani, Aria, Vakili et al., The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Life Sciences,
doi:10.1016/j.lfs.2020.118167Atçalı, Yakut, Çağlayan, Ulucan, Kara, Effects of favipiravir on hematologic parameters and bone marrow in the rats, Journal of Experimental and Clinical Medicine
Bert, Tan, Kunasegaran, Tham, Hafezi et al., SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls, Nature,
doi:10.1038/s41586-020-2550-zCiaccio, Agnello, Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19), Diagnosis (Berl),
doi:10.1515/dx-2020-0057De Clercq, New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections, Chem Asian J,
doi:10.1002/asia.201900841Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci,
doi:10.2183/pjab.93.027Gul, Kurt, Capraz, Ozturk, Effect of Favipiravir Use on INR, PT, aPTT Tests of COVID-19 Patients Sabuncuoglu, Serefeddin Health Science
Mir, Tahamtan, Nikoo, Arabi, Moradi et al., Evaluation of biochemical characteristics of 183 COVID-19 patients: A retrospective study, Gene Rep,
doi:10.1016/j.genrep.2021.101448Shang, Wan, Liu, Yount, Gully et al., Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry, PLoS Pathog,
doi:10.1371/journal.ppat.1008392Thachil, What do monitoring platelet counts in COVID-19 teach us, Journal of Thrombosis and Haemostasis,
doi:10.1111/jth.14879Wang, Zhong, Salam, Tarning, Zhan et al., Phase 2a, openlabel, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza, EBioMedicine,
doi:10.1016/j.ebiom.2020.103125Yang, Cao, Qin, Wang, Cheng et al., Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China, J Infect,
doi:10.1016/j.jinf.2020.02.016Yaylaci, Dheir, Senocak, Genc, Kocayigit et al., The effects of favipiravir on hematological parameters of covid-19 patients, Rev Assoc Med Bras,
doi:10.1590/1806-9282.66.S2Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3Zinellu, Paliogiannis, Carru, Mangoni, INR and COVID-19 severity and mortality: A systematic review with meta-analysis and meta-regression, Adv Med Sci,
doi:10.1016/j.advms.2021.07.009{ 'indexed': {'date-parts': [[2023, 6, 23]], 'date-time': '2023-06-23T07:41:01Z', 'timestamp': 1687506061140},
'reference-count': 7,
'publisher': 'Amasya University',
'issue': '3',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'accepted': {'date-parts': [[2022, 12, 19]]},
'abstract': '<jats:p xml:lang="en">The 2019 coronavirus disease (COVID-19) has caused millions of cases '
'worldwide. As the pandemic progresses, understanding the effects of this disease remains '
'important. We aimed to examine the hematological effects of the disease. The research was '
'carried out as a retrospective study, 50 patients using favipiravir and 50 patients not using '
'favipiravir who had positive COVID-19 RT-PCR test in nasal and throat swabs were included in '
'the study. INR, PTT, aPTT tests were evaluated on all patients. Results of patients using '
'favipiravir; INR 1.3±0.2, PT(s) 16.4±3.4, aPTT(s) 40.7±10.1, while the results of patients '
'who did not use favipiravir were INR 1,2±0.2, PT(s) 14.6±2.5, aPTT(s) was found 38.4±7.8. '
'While PT and INR were found to significantly higher in patients using favipiravir '
'(p&lt;0.05), the elevation in aPTT values was not significant. As a consequence, it was '
'obtained that favipiravir prolongs the clotting time. In the light of these results, it is '
'recommended to consider this in anticoagulant therapy used for treatment.</jats:p>',
'DOI': '10.55895/sshs.1213382',
'type': 'journal-article',
'created': { 'date-parts': [[2022, 12, 19]],
'date-time': '2022-12-19T08:38:41Z',
'timestamp': 1671439121000},
'page': '14-20',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Effect of favipiravir use on INR, PT, aPTT tests of COVID-19 patients',
'prefix': '10.55895',
'volume': '4',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-5849-0116',
'authenticated-orcid': True,
'given': 'Mehmet Ali',
'family': 'GÜL',
'sequence': 'first',
'affiliation': [{'name': 'AMASYA ÜNİVERSİTESİ, TIP FAKÜLTESİ'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-1685-5332',
'authenticated-orcid': True,
'given': 'Nezahat',
'family': 'KURT',
'sequence': 'additional',
'affiliation': [{'name': 'Erzincan Binali Yıldırım Üniversitesi Tıp Fakültesi'}]},
{ 'ORCID': 'http://orcid.org/0000-0001-9586-6509',
'authenticated-orcid': True,
'given': 'Mustafa',
'family': 'ÇAPRAZ',
'sequence': 'additional',
'affiliation': [{'name': 'AMASYA ÜNİVERSİTESİ, TIP FAKÜLTESİ'}]},
{ 'ORCID': 'http://orcid.org/0000-0003-4525-3477',
'authenticated-orcid': True,
'given': 'Alpaslan',
'family': 'ÖZTÜRK',
'sequence': 'additional',
'affiliation': [ { 'name': 'Sağlık Bilimleri Üniversitesi, Ankara Dışkapı Yıldırım Beyazıt '
'Eğitim ve Araştırma Hastanesi,'}]}],
'member': '7009',
'published-online': {'date-parts': [[2023, 1, 3]]},
'reference': [ { 'key': 'ref1',
'doi-asserted-by': 'crossref',
'unstructured': 'Ciaccio, M., & Agnello, L. (2020). Biochemical biomarkers alterations in '
'Coronavirus Disease 2019 \r\n'
'(COVID-19). Diagnosis (Berl), 7(4), 365-372. doi:10.1515/dx-2020-0057',
'DOI': '10.1515/dx-2020-0057'},
{ 'key': 'ref2',
'doi-asserted-by': 'crossref',
'unstructured': 'Connors, J. M., & Levy, J. H. (2020). COVID-19 and its implications for '
'thrombosis and \r\n'
'anticoagulation. Blood, 135(23), 2033-2040. doi:10.1182/blood.2020006000',
'DOI': '10.1182/blood.2020006000'},
{ 'key': 'ref3',
'doi-asserted-by': 'crossref',
'unstructured': 'Conway, E. M., Mackman, N., Warren, R. Q., Wolberg, A. S., Mosnier, L. '
'O., Campbell, R. A., . . . \r\n'
'Morrissey, J. H. (2022). Understanding COVID-19-associated coagulopathy. '
'Nat Rev Immunol, \r\n'
'22(10), 639-649. doi:10.1038/s41577-022-00762-9',
'DOI': '10.1038/s41577-022-00762-9'},
{ 'key': 'ref4',
'doi-asserted-by': 'crossref',
'unstructured': 'Mir, S. M., Tahamtan, A., Nikoo, H. R., Arabi, M. S., Moradi, A. W., '
'Ardakanian, S., & Tabarraei, A. \r\n'
'(2022). Evaluation of biochemical characteristics of 183 COVID-19 '
'patients: A retrospective \r\n'
'study. Gene Rep, 26, 101448. doi:10.1016/j.genrep.2021.101448',
'DOI': '10.1016/j.genrep.2021.101448'},
{ 'key': 'ref5',
'doi-asserted-by': 'crossref',
'unstructured': 'Thachil, J. (2020). What do monitoring platelet counts in COVID-19 teach '
'us? Journal of \r\n'
'Thrombosis and Haemostasis, 18(8), 2071-2072. doi:10.1111/jth.14879',
'DOI': '10.1111/jth.14879'},
{ 'key': 'ref6',
'doi-asserted-by': 'crossref',
'unstructured': 'Tuğçe Atcali , S. Y., Cüneyt Çağlayan , Aykut Ulucan , Adem Kara. '
'(2021). Effects of favipiravir on \r\n'
'hematologic parameters and bone marrow in the rats. J Exp Clin Med, '
'39(1), 156-159.',
'DOI': '10.52142/omujecm.39.1.31'},
{ 'key': 'ref7',
'doi-asserted-by': 'crossref',
'unstructured': 'Yaylaci, S., Dheir, H., Senocak, D., Genc, A. B., Kocayigit, H., Cekic, '
'D., . . . Karabay, O. (2020). The \r\n'
'effects of favipiravir on hematological parameters of covid-19 patients. '
'Rev Assoc Med Bras \r\n'
'(1992), 66Suppl 2(Suppl 2), 65-70. doi:10.1590/1806-9282.66.S2.65\r\n'
'Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., . . . Cao, B. '
'(2020). Clinical course and risk factors for \r\n'
'mortality of adult inpatients with COVID-19 in Wuhan, China: a '
'retrospective cohort study. \r\n'
'Lancet, 395(10229), 1054-1062. doi:10.1016/S0140-6736(20)30566-3',
'DOI': '10.1590/1806-9282.66.s2.65'}],
'container-title': 'Sabuncuoglu Serefeddin Health Sciences',
'original-title': [],
'deposited': { 'date-parts': [[2023, 6, 22]],
'date-time': '2023-06-22T04:11:08Z',
'timestamp': 1687407068000},
'score': 1,
'resource': {'primary': {'URL': 'http://dergipark.org.tr/en/doi/10.55895/sshs.1213382'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 1, 3]]},
'references-count': 7,
'journal-issue': {'issue': '3', 'published-online': {'date-parts': [[2023, 1, 3]]}},
'URL': 'http://dx.doi.org/10.55895/sshs.1213382',
'relation': {},
'ISSN': ['2667-6338'],
'published': {'date-parts': [[2023, 1, 3]]}}
